{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:41:15Z","timestamp":1759585275978,"version":"build-2065373602"},"reference-count":4,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.eururo.2011.07.056","type":"journal-article","created":{"date-parts":[[2011,8,4]],"date-time":"2011-08-04T17:27:34Z","timestamp":1312478854000},"page":"e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men with Metastatic Castration-Resistant Prostate Cancer. Eur Urol 2012;61:363\u20139"],"prefix":"10.1016","volume":"61","author":[{"given":"YiJun","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DingWei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2011.07.056_bib0025","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.eururo.2011.06.034","article-title":"Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer","volume":"61","author":"Pond","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.07.056_bib0010","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s10147-008-0814-y","article-title":"Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients","volume":"14","author":"Soga","year":"2009","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.07.056_bib0015","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2010.08.044","article-title":"Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer","volume":"77","author":"Mountzios","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.07.056_bib0020","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cncr.23163","article-title":"Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel","volume":"112","author":"Beer","year":"2008","journal-title":"Cancer"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811007949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811007949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:04:30Z","timestamp":1759583070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283811007949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":4,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0302283811007949"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2011.07.056","relation":{},"ISSN":["0302-2838"],"issn-type":[{"type":"print","value":"0302-2838"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men with Metastatic Castration-Resistant Prostate Cancer. Eur Urol 2012;61:363\u20139","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2011.07.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2011.06.034","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2011 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}